CLDN2: A Potential Drug Target for Hypertension, Heart Failure and Cancer

Target Name: CLDN2

NCBI ID: G9075

CLDN2

CLDN2: A Potential Drug Target for Hypertension, Heart Failure and Cancer

CLDN2 (CLD2-HUMAN) is a protein that is expressed in the endothelial cells of the body. It is a member of the gene family known as claudin, which is responsible for the production of tight junctions, which are a type of cell-cell barrier. CLDN2 is highly expressed in various tissues, including the placenta, liver, and kidneys. Its function is not well understood, but it is thought to play a role in the regulation of blood pressure, and it is also suggested to be involved in the development and progression of certain diseases, such as heart failure and cancer. As a drug target or biomarker, CLDN2 is of interest to researchers because it may provide new insights into the mechanisms underlying these diseases and may lead to the development of new treatments.

One of the main functions of CLDN2 is its role in the regulation of blood pressure. CLDN2 is known to interact with the protein E-cadherin, which is also a tight junction protein. This interaction allows CLDN2 to regulate the amount of blood that enters the body through the endothelial cells. This is important for maintaining a stable blood pressure and is critical for maintaining proper circulation.

Another function of CLDN2 is its role in the development and progression of certain diseases. For example, studies have shown that CLDN2 is highly expressed in the placenta, which is the organ responsible for providing oxygen and nutrients to the developing fetus. This suggests that CLDN2 may be involved in the regulation of fetal growth and development. Additionally, CLDN2 has also been shown to be involved in the development and progression of certain cancers, such as breast cancer.

As a drug target or biomarker, CLDN2 is of interest to researchers because it may provide new insights into the mechanisms underlying these diseases and may lead to the development of new treatments. For example, researchers may be interested in using CLDN2 as a target for new drugs that can treat hypertension, heart failure, and certain cancers. Additionally, studying the role of CLDN2 in the regulation of blood pressure and its involvement in the development and progression of diseases may also provide new insights into the underlying mechanisms of these diseases and may lead to the development of new treatments.

In conclusion, CLDN2 is a protein that is expressed in the endothelial cells of the body that plays a role in the regulation of blood pressure and the development and progression of certain diseases. As a drug target or biomarker, CLDN2 is of interest to researchers because it may provide new insights into the mechanisms underlying these diseases and may lead to the development of new treatments. Further research is needed to fully understand the role of CLDN2 in the regulation of blood pressure and its involvement in the development and progression of diseases.

Protein Name: Claudin 2

Functions: Plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity

The "CLDN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLDN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets